Table 1 Baseline patient characteristics

From: Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

 

Total sample ( n =750)

US group ( n =347) a

EU group ( n =274) a

Total US vs total EU

 

Sunitinib ( n =375)

IFN- α (n =375)

Sunitinib ( n =179)

IFN- α (n =168)

Sunitinib ( n =135)

IFN- α (n =139)

diff. US vs EU P -value

Mean age, years (range)

61 (27–87)

60 (34–85)

61 (39–87)

60 (34–85)

61 (27–80)

60 (39–82)

0.8735

Male/female (%)

71/29

72/28

78/22

65/35

65/35

83/17

0.5172

Race/Ethnicity (%)

0.0004 (<0.0001b)

 Asian

1.87

3.20

1.68

3.57

0.74

0.72

 

 Black

1.07

2.67

1.12

4.76

0.74

1.44

 

 Not allowed to ask

0.27

0.27

0

0.60

0

0

 

 Not listed

2.40

3.47

5.03

5.95

0

1.44

 

 White

94.40

90.40

92.18

85.12

98.52

96.40

 

Previous nephrectomy (%)

90

89

92

91

90

91

0.7363

Previous radiation therapy (%)

14

14

13

12

16

14

0.3428

Common sites of metastases (%)

 Lung

78

79

83

82

71

77

0.0152

 Liver

26

24

30

27

24

19

0.0601

 Bone

30

30

31

26

31

30

0.5115

 Lymph nodes

58

53

53

46

67

60

0.0004

Number of disease sites (%)

0.0837

 1

14

19

11

18

17

25

 

 2

29

30

31

30

27

28

 

 ⩾3

57

51

58

51

56

47

 

ECOG PS (%)

0.0115 (0.0075c)

 0

62

61

67

68

57

58

 

 1

38

38

33

31

43

40

 

 2

0

1

0

1

0

2

 
  1. Abbreviations: IFN-α=interferon-α; ECOG PS=Eastern Cooperative Oncology Group.
  2. a In our previous publication (Cella et al, 2008) one patient in the US sample was inadvertently assigned to the EU sample. This paper, with 274 (instead of 275) patients in the EU group and 347 (instead of 346) in the US group, gives the correct allocation.
  3. b All but ‘white’ races collapsed in a ‘not white’ category.
  4. c ECOG 1 and 2 collapsed in one category, ECOG ⩾1.
Back to article page